1. Home
  2. GROV vs CALC Comparison

GROV vs CALC Comparison

Compare GROV & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

HOLD

Current Price

$1.06

Market Cap

44.8M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$1.59

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROV
CALC
Founded
2016
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
19.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
GROV
CALC
Price
$1.06
$1.59
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $50.00
AVG Volume (30 Days)
★ 67.4K
62.0K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.26
N/A
EPS
★ N/A
N/A
Revenue
★ $173,716,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.14
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.86
$0.44
52 Week High
$1.57
$7.20

Technical Indicators

Market Signals
Indicator
GROV
CALC
Relative Strength Index (RSI) 52.16 46.84
Support Level $0.99 $0.51
Resistance Level $1.15 $2.31
Average True Range (ATR) 0.05 0.12
MACD 0.00 -0.08
Stochastic Oscillator 58.71 3.85

Price Performance

Historical Comparison
GROV
CALC

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: